Amal Arahmani
Brussels, BRU, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.
Journal: JAMA oncology
Published: December 18, 2025
Author Correction: Advancing equitable access to innovation in breast cancer.
Journal: NPJ breast cancer
Published: December 16, 2025
Advancing equitable access to innovation in breast cancer.
Journal: NPJ breast cancer
Published: April 03, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).
Journal: ESMO open
Published: November 14, 2024
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.
Journal: Future oncology (London, England)
Published: August 23, 2023
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 14, 2022
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Journal: The New England journal of medicine
Published: June 03, 2021
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
Journal: British journal of cancer
Published: June 10, 2020
Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 09, 2019
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Journal: Clinical breast cancer
Published: February 21, 2019
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: June 06, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026